Continuity of Treatment

Enable echinocandin continuity of treatment

Simplify your patients’ treatment

Daily intravenous administration of currently approved echinocandins for invasive candidiasis may delay discharge or limit the continuity of echinocandin therapy through discharge.1

A once-weekly IV infusion of REZZAYO® could2:

Allow for earlier discharge of patients on echinocandins who are otherwise dischargeable3

Eliminate the need for dose modification of concomitant medications due to drug-drug interactions2

Help minimize the potential for inadequate Candida antifungal coverage for patients with azole-resistant isolates or isolates of unknown susceptibility4

Limitations of Use
REZZAYO® has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida.

When patients are ready, you can set them on the path to echinocandin continuity of treatment with REZZAYO®

REZZAYO® offers a new option for continuity of echinocandin treatment in the outpatient setting

Potential benefits of treatment with
once-weekly REZZAYO®:

May be more convenient and manageable for patients to schedule weekly rather than daily infusions1,5

May be logistically easier for outpatient infusion vs daily infusions1,5

Allows providers to maintain patients on recommended echinocandin therapy until treatment is complete1,5

No need for a PICC line and associated maintenance, risk of complications, and discomfort from the device1,5

No known clinically significant drug-drug interactions, and no dose adjustment is needed for any known factors2

May provide greater transparency into adherence with 7 days of therapy in every dose2

PICC=peripherally inserted central catheter.

When patients are ready, help them access REZZAYO®

Find Out How to Order

INDICATION AND USAGE

REZZAYO® (rezafungin for injection) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data.

Limitations of Use

REZZAYO® has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida.

IMPORTANT SAFETY INFORMATION

Contraindications

REZZAYO® is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.

Warnings and Precautions

  • Infusion-related Reactions: REZZAYO® may cause infusion-related reactions, including flushing, sensation of warmth, urticaria, nausea, or chest tightness. If these reactions occur, slow or pause the infusion.
  • Photosensitivity: REZZAYO® may cause photosensitivity. Advise patients to use protection from sun exposure and other sources of UV radiation.
  • Hepatic Adverse Reactions: Abnormalities in liver tests have been seen in clinical trial patients treated with REZZAYO®. Monitor patients who develop abnormal liver tests and evaluate patients for their risk/benefit of continuing REZZAYO® therapy.

Adverse Reactions

Most common adverse reactions (incidence ≥ 5%) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia.

Please see full Prescribing Information for REZZAYO® (rezafungin for injection).

See more

INDICATION AND USAGE

REZZAYO® (rezafungin for injection) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the

IMPORTANT SAFETY INFORMATION

Contraindications

REZZAYO® is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.

References:1. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026. doi:10.1038/nrdp.2018.26 2. REZZAYO®. Prescribing information. Melinta Therapeutics, LLC; 2023. 3. Melinta Therapeutics. Data on file. 2023. 4. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. doi:10.1093/cid/civ933 5. Guinea J. Rezafungin and invasive candida infections: a new game changing antifungal? Lancet. 2023;401(10370):3-5. doi:10.1016/S0140-6736(22)02371-6